Immune Checkpoint Regulation: The role of the PD-1/PDL1 pathway.

October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable  or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell …

Nivolumab (Opdivo) demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer (NSCLC) Read more »

September 11, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Pembrolizumab (Keytruda) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Melanoma, which accounts for approximately 5 …

Pembrolizumab [Keytruda] for advanced melanoma: First PD-1 blocking drug to receive approval Read more »